Multidistrict Litigation Mulled for Actos Bladder Cancer Cases
An assembly of federal judges is scheduled to meet in December and decide whether or not to consolidate individual product liability lawsuits against Takeda Pharmaceuticals over the link between the diabetes drug Actos and bladder cancer into a single multidistrict litigation.
On Dec. 1, the U.S. Judicial Panel on Multidistrict Litigation will convene in Savannah, Ga., to hear arguments over a motion to concentrate individual suits filed by diabetics who claim they developed bladder cancer after being prescribed Actos to control type 2 diabetes. Actos has also been associated with an increased risk for heart failure and diabetic macular edema.
Hundreds of lawsuits have been filed in district courts across the country alleging that Takeda failed to warn patients of the potential side-effects of Actos, including an increased risk for bladder cancer among diabetics who took the higher 80-milligram daily dose of the drug for 12 months or longer.
Actos was approved by the Food and Drug Administration (FDA) in 1999 for use in controlling blood-sugar levels for patients with type 2 diabetes, which is the most common form of the disease.
If the federal judicial panel agrees to consolidate the Actos cases into multidistrict litigation, the individual lawsuits involving the ties between Actos and the development of bladder cancer would be heard by the same judge.
If you are an Actos user who was diagnosed with bladder cancer, an experienced dangerous drug attorney may be able to help you pursue financial compensation. Please contact us for a free case evaluation and to get in touch with an Actos lawyer near you.